Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Olink Bioscience Introduces Proseek Multiplex CVD I 96x96

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
A 92 protein biomarker panel for cardiovascular disease.

Olink Bioscience has launched Proseek Multiplex CVD I 96x96, a new protein biomarker panel in the Proseek Multiplex product line which targets cardiovascular disease.

This panel will be an important tool in the search for new multivariate protein biomarker expression patterns that could improve prediction and prognosis of disease.

Cardiovascular disease is the number one cause of death worldwide and a growing health problem that requires massive medical intervention each year. Reversing this trend requires, apart from healthier lifestyles, improved diagnostic and prognostic tools.

New and relevant protein biomarkers are essential components of these tools and therefore a pre-requisite for developing improved and personalized treatment.

Proseek Multiplex CVD I 96x96 is a high throughput multiplex immunoassay which speedily allows analysis of 92 cardiovascular-related protein biomarkers across 96 samples simultaneously without any compromise in data quality. Only one microliter of sample is required, economizing on precious or biobanked clinical material.

When used in conjunction with Fluidigm’s BioMark HD System, Olink Bioscience’s Proseek Multiplex technologies provide researchers with the highest throughput multiplexing solution for protein biomarker discovery in the market.

Typically, researchers are limited to working with a few tens-of-protein biomarkers at a time. Using the BioMark HD System with the Proseek Multiplex CVD I 96x96, a researcher can now obtain results for up to 9,216 reactions in just a few hours.

“It is a very exciting opportunity when Olink can offer a new tool for researchers, clinicians and anyone interested in cardiovascular diseases. It’s well known that all individuals are different and in an ideal world could receive personalized medicine and care. We would like to contribute to fulfilling that dream faster by helping to find new protein expression patterns that could serve as biomarkers” says Andrea Ballagi, Director Commercial Operations at Olink Bioscience.

The Proseek Multiplex CVD I 96x96 panel contains known cardiovascular and inflammatory markers as well as a few exploratory proteins which have great potential as new cardiovascular markers.

The exploratory markers are intracellular proteins which were unexpectedly detected in serum or plasma samples, demonstrating that Proseek Multiplex is a sensitive tool for analyzing proteins in body fluids.

Fluidigm’s BioMark HD System is a multi-application genomics and proteomics platform that provides results equivalent to the gold standards for every respective experimental approach.

The system produces high-quality data from RNA, miRNA and DNA from sample sizes down to the single cell level - and now extends to proteins. The BioMark HD System performs analysis of protein expression, gene expression, copy number variation, SNP genotyping, and digital PCR.

“The cardiovascular panel has already attracted a lot of interest among cardiovascular researchers; we have many customers knocking on our door eager to start analyzing their own clinical samples. We have already performed some initial testing of the panel and the results look very promising. We are very excited about the possibilities Proseek Multiplex CVD I 96x96 offers to the cardiovascular research community and pharmaceutical industry” says Agneta Siegbahn, Professor in Clinical Coagulation Science, Department of Medical Sciences, Uppsala University and Managing Director of Clinical Biomarkers Facility at Science for Life Laboratory in Uppsala, Uppsala University, one of Olink’s service providers.

Proseek Multiplex is based on the proprietary PEA technology developed at Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens.

Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

Proseek Multiplex CVD I 96x96 is the second panel from Olink. The company has launched the Proseek Multiplex Oncology I 96x96 product previously this year. Both are for research use only.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New European Consortium to Boost our Understanding of IBD
A multi-modal integrated biomarker study Consortium to increase diagnostic precision in detection of the diseases.
Thursday, May 23, 2013
Olink Bioscience Appoints Sigma-Aldrich as Distributor of Duolink
Olink Bioscience will continue to develop the protein biomarker market.
Friday, May 17, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!